Alloush Ramsey 4

What Happened

Alloush Ramsey, Chief Operating Officer of Journey Medical Corp (DERM), was granted equity awards on April 22, 2026: 46,863 restricted stock units (RSUs) and 62,795 stock options. The Form 4 reports an acquisition price of $0.00 for both grants (these are compensation awards, not purchases or sales). The RSUs and options vest in equal annual installments over three years.

Key Details

• Transaction date: April 22, 2026; Form 4 filed April 24, 2026 (appears timely).
• Grants reported: 46,863 RSUs (reported as award A) and 62,795 stock options (reported as derivative award A). Reported acquisition price: $0.00 (no cash paid).
• RSU vesting (per footnote): 15,621 shares vest on each of Apr 22, 2027; Apr 22, 2028; Apr 22, 2029.
• Option vesting (per footnote): 20,932 options vest on Apr 22, 2027; 20,932 on Apr 22, 2028; 20,931 on Apr 22, 2029.
• Shares owned after transaction: not specified in the provided summary of the filing.
• Footnotes: F1/F3 detail the three-year vesting schedule; F2 notes inclusion of restricted stock units that vest over various periods. No 10b5-1 plan, tax withholding, or cashless-exercise language was disclosed in the summary provided.

Context

RSUs convert to common shares as they vest; stock options give the holder the right to buy shares at a set exercise price once vested (the exercise price and post-vesting actions were not disclosed in the summary). These grants are routine executive compensation and do not represent an open-market purchase or sale by the insider. They do not, by themselves, indicate immediate buying or selling of company stock.